Home / Health / Vertex Drug Shows Promise in Kidney Disease Trial
Vertex Drug Shows Promise in Kidney Disease Trial
10 Mar
Summary
- Experimental drug povetacicept met its main goal in a late-stage trial.
- Patients showed a significant reduction in urine protein leakage.
- Vertex Pharmaceuticals shares rose about 10% after the announcement.
Vertex Pharmaceuticals revealed on Monday that its investigational drug, povetacicept, has achieved its primary objective in a pivotal late-stage clinical study. The drug is being developed for patients diagnosed with IgA nephropathy, a serious autoimmune condition capable of causing kidney failure.
Participants receiving povetacicept demonstrated a notable 52% decrease in urine protein leakage after 36 weeks of treatment. This outcome contrasts sharply with the minimal 4.3% reduction observed in the placebo group, underscoring the drug's potential efficacy.
In response to the trial results, Vertex Pharmaceuticals saw its stock price surge by approximately 10% during after-hours trading. The company continues to advance its development pipeline for significant unmet medical needs.
